Life Sciences AISeedWorkflow signalℹ83Proxima Bio
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Why people are saving it
Relevant for biotech investors and drug discovery teams tracking AI approaches to protein network modulation beyond single-target inhibition.
What they're building
Proxima Bio builds AI-native drug discovery tools that map protein-protein interactions to design medicines capable of reshaping entire protein networks.
Founders
Zachary Carpenter
Co-founder & CEO
Luca Naef
Co-founder & CTO
Foundation model usage
Proxima Bio applies models to biological data where retrieval, structure, and multimodal reasoning matter.
NYC footprint
Proxima Bio is part of the New York City AI startup scene, with a profile focused on its market category, stage, and product signal.
Funding
Latest funding: Seed · $80M · January 2026. Total raised: $80M. Lead investor: DCVC.
Platform / OpenAI fit
Strong fit for multimodal reasoning, biological data retrieval, molecule and protein analysis, structured extraction, and research copilots.
Notes
Proxima Bio is tagged workflow signal based on buyer clarity, repeat workflow signal, public activity, and fit with the AI Atlas map.
Related NYC startups
Protein interaction maps for drug discovery
Serinus Biosciences uses a knowledge-primed AI engine to design cancer combination therapies by mapping how tumor cells evolve treatment resistance and identifying molecules that override resistance escape routes.
Life Sciences AIWorkflow signalℹ124viewsRecent Activity
Protein interaction maps for drug discovery
Output Biosciences is building Large Biological Models, generative AI architectures designed to handle the long, nonlinear, fragmented data of biological systems across molecules, cells, and organisms.
Life Sciences AIWorkflow signalℹ29viewsRecent Activity